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Abstract
Context: We are going to face an epidemic of severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus in our country. The
main manifestation of this viral infection is respiratory and cardiovascular; however, up-to-date knowledge of its probable neuro-
logic complications is highly needed.
Evidence Acquisition: To provide up-to-date information on neurologic manifestation on coronaviruses, we concisely reviewed
the neurologic manifestations and their complications. Using the keywords, coronavirus, corona, human coronaviruses (HCoVs),
SARS, Middle East respiratory syndrome-related (MERS), coronavirus disease 2019 (COVID-19), manifestations, complications, and
neurologic, all the relevant articles were retrieved from PubMed, reviewed, and critically analyzed.
Results: Although the main clinical manifestation of human coronaviruses is respiratory involvement and the main cause of death
is acute respiratory failure, extra respiratory manifestations such as neurologic findings have been reported. Fortunately, the neu-
rologic manifestations in COVID-19 have not been reported yet.
Conclusions: We need well-designed studies to monitor neurologic manifestations of COVID-19 in adults and children.
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1. Context
Investigators described coronaviruses (CoVs) in the
1960s for the first time (1). The CoVs are a family of viruses
that cause a variety of diseases in mammals and birds. The
earliest reports were in chickens infected by two groups of
viruses called human coronavirus 229E and human coro-
navirus OC43 and showed the clinical manifestations of
the common cold (2). They belong to the subfamily Or-
thocoronavirinae, the member of the Coronaviridae fam-
ily, the order of Nidovirales, and the kingdom of Riboviria
(3, 4). They are a large family of single-stranded RNA viruses
with a genome size of about 27 - 34 kb, which is the largest
genome compared with other RNA viruses (5). Corona is a
Latin term, meaning “crown”, due to the surface covering
in club-shaped protein spikes of virions (the infective form
of a virus) by electron microscopy. The CoVs contain spike
(S), envelope (E), membrane (M), and nucleocapsid (N) as
proteins forming their overall structure. After entry into
the host cell, the virus particle is uncoated, followed by en-
tering the genome to the cytoplasm (6).
There are seven strains of human CoVs, including
Human coronavirus 229E (HCoV-229E), Human coron-
avirus HKU1, Middle East respiratory syndrome-related
coronavirus (MERS-CoV), severe acute respiratory syn-
drome coronavirus (SARS-CoV), human coronavirus NL63
(HCoV-NL63, new haven coronavirus), Human coronavirus
OC43 (HCoV-OC43), SARS-CoV-2 or “novel coronavirus 2019”
(2019-nCoV) (7).
The CoV subfamily has categorized into four genera of
alpha, beta, gamma, and delta CoVs. The human coron-
aviruses (HCoVs) can be found in alpha CoVs (HCoV-229E
and HCoV-NL63) and beta CoVs (HCoV-HKU1, HCoV-OC43,
MERS-CoV, SARS-CoV, and SARS-CoV-2). The CoV family, in-
cluding SARS-CoV, HCoV NL63, HKU1, MERS-CoV, and SARS-
CoV-2, was identified in 2003, 2004, 2005, 2012, and 2019,
respectively. Human-to-human transmission of CoVs is be-
lieved to occur through respiratory droplets from sneezing
and coughing (8).
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2. Evidence Acquisition
To provide up-to-date information on neurologic man-
ifestation of CoVs, we concisely reviewed the neurologic
manifestations and their complications. Using the key-
words, including coronavirus, corona, HCoVs, SARS, MERS,
COVID-19, manifestations, complications, and neurologic,
all relevant articles were retrieved from PubMed, reviewed,
and critically analyzed.
3. Results
3.1. Common Clinical Manifestations
Some CoVs only affect animals, but a number of them
can also affect humans. Symptoms are different in dif-
ferent species: chickens represent upper respiratory tract
infections (URTIs), whereas cows and pigs have diarrhea.
HCoVs infections are linked to respiratory and extra respi-
ratory tract symptoms and can affect the central nervous
system. In addition, in contrast to different RNA viruses,
HCoVs are easily mutated and recombined after infecting
the same cells by various strains and resulting in a new
virus with unexpected host ranges as well as pathogenicity
(9).
Common HCoVs, such as 229E, NL63, OC43, and HKU1,
result in mild to moderate URTIs, including common cold
(runny nose, sore throat, headache, fever, cough, and feel-
ing of illness). Investigators believed that CoVs account
for 15% - 30% of total common colds among adults and
children, primarily in the winter and early spring seasons.
Most people could be infected with CoVs during their lives.
Lower respiratory tract infections (LRTIs) are caused by
HCoVs, like pneumonia or bronchitis (direct viral or sec-
ondary bacterial) (10), which mostly affect those with car-
diopulmonary disease, various immune system deficien-
cies, infants, and elderly. Rare forms of HCoVs, includ-
ing SARS and MERS, lead to both LRTIs and URTIs and can
be lethal (10). The prevalence of atypical pneumonia was
announced in December 2019 in Wuhan, China, as a new
strain of CoV and called 2019-nCoV by the World Health Or-
ganization, which was then called SARS-CoV-2 according to
the International Committee on Taxonomy of Viruses (11).
Coronavirus disease 2019 (COVID-19) has special pathogen-
esis due to causing both LRTIs and URTIs and its lethal fea-
ture. The HCoVs were found in upper respiratory tract se-
cretions collected in 30% of acute respiratory infections
and wheezy bronchitis in cases younger than six years
with recurrent respiratory infections (12). Abdominal pain,
emesis, and diarrhea are the initial manifestations of acute
infections by non-SARS HCoVs. Such findings have also
been announced, especially in the HCoV-OC43 and HCoV-
NL63, that are possibly the direct outcomes of viral inva-
sion along with the mucosa of the intestine (9).
3.2. Neurologic Manifestations
Members of Coronaviridae can cause respiratory, in-
testinal, hepatic, and neurological diseases of various
severities in humans and animals. The clear involvement
of several animal CoVs in acute and chronic neurologic
diseases resulted in a search for similar pathogenicity of
human CoVs. Community-acquired HCoVs can infect neu-
ral cells in vitro (13), and three-week-old mice develop
generalized encephalitis after intracerebral inoculation
with HCoV-OC43 (14). In another case report, HCoV-OC43
RNA was recovered from the brain, at autopsy, in an 11-
month-old boy with severe combined immunodeficiency
and acute encephalitis (15).
3.3. Demyelinating Disorders
The CoVOC43 was found in the cerebrospinal fluid
(CSF) and nasopharyngeal secretions of a 15-year-old boy
that admitted with the diagnosis of ADEM as the earliest
announced link between HCoV and ADEM. This report con-
firms that CoV plays an important role in demyelinating
disease in humans (16). Some investigators proposed a link
between CoVs and multiple sclerosis (MS), but current evi-
dence is inconclusive. T cell clones from patients with MS
have been shown to react to both HCoV-229E antigens and
myelin basic protein, suggesting molecular mimicry as a
basis of pathogenesis (16). Some, but not all, investigators
have detected RNA of the human CoVs, HCoV-OC43, and
HCoV-229E, more frequently in brain tissue of cases with
MS through reverse-transcriptase polymerase chain reac-
tion than in healthy individuals (17). Despite these reports,
an etiologic link between CoVs and demyelinating disor-
ders such as MS or ADEM has not been proven.
Arabi et al. (18) reported a severe neurologic syn-
drome associated with MERS CoV infections. The neuro-
logic symptoms are alterations in mental state that range
from confusion to coma, ataxia, and focal motor impair-
ments. According to the results of brain MRI, new-onset
widespread, two-sided hyperintensities on T2WI in white
matter as well as subcortical regions of the frontal, tem-
poral, and parietal lobes, the basal ganglia and corpus
callosum, pons, cerebellum, and upper cervical cord (18).
The HCoVs could cause neurological symptoms such as
seizures and meningoencephalitis in children (19).
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3.4. Acute Flaccid Paralysis
In particular, HCoV OC43 is a neurotrophic, neuroinva-
sive, and neuroinflammatory virus. Experimental animal
studies reported that HCoV OC43 causes flaccid paralysis
and demyelination (AFP) (20). Although HCoVs as a cause
of AFP has not been reported until now (19), HCoV 229E and
OC43 co-infection may cause respiratory failure and AFP
(21).
3.5. Neurologic Complications During Treatment
Sometimes neurologic complications may be seen dur-
ing the treatment of HCoVs infections. Kim et al. (22)
revealed that neurological symptoms could be observed
throughout or following MERS-CoV therapy. Bickerstaff’s
encephalitis overlapping with Guillain-Barre syndrome,
intensive-care-unit-acquired weakness, or other toxic or
infectious neuropathies were the possible diagnoses pre-
sented for these four cases out 23 referred MERS cases (22).
3.6. Neurologic Complications of COVID-19
Although from the December 2019, outbreak of a novel
coronavirus (SARS-CoV-2) or COVID-19 started in Wuhan
and has become a global threat to human health in a short
time, fortunately, significant neurological manifestations
were not reported until now.
4. Conclusions
HCoVs can infect humans and animals. Moreover,
HCoVs infections are accompanied by common respiratory
and uncommon extra respiratory symptoms and can affect
the central nervous system. The HCoVs have been causing
worldwide outbreaks with high morbidity and mortality.
Fortunately, neurological manifestations are not common
but reported during the acute phase and treatment period.
Footnotes
Authors’ Contribution: Study concept and design: Mah-
moud Reza Ashrafi, Morteza Heidari, and Ali Reza Tava-
soli. Drafting the manuscript: Reza Azizimalamir, Reza
Shervin Badv, Mohammad Vafaee-Shahi, and Ali Nikkhah.
Critical revision of the manuscript for important intel-
lectual content: Mahmoud Reza Ashrafi, Morteza Heidari,
and Hadi Montazerlotfelahi. Study supervision: Mahmoud
Reza Ashrafi and Morteza Heidari.
Conflict of Interests: Authors declare no conflict of inter-
est.
Funding/Support: This research did not receive any spe-
cific grant from funding agencies in the public, commer-
cial, or not-for-profit sectors.
References
1. Kahn JS, McIntosh K. History and recent advances in coronavirus dis-
covery. Pediatr Infect Dis J. 2005;24(11 Suppl):S223–7. discussion S226.
doi: 10.1097/01.inf.0000188166.17324.60. [PubMed: 16378050].
2. Geller C, Varbanov M, Duval RE. Human coronaviruses: Insights
into environmental resistance and its influence on the devel-
opment of new antiseptic strategies. Viruses. 2012;4(11):3044–68.
doi: 10.3390/v4113044. [PubMed: 23202515]. [PubMed Central:
PMC3509683].
3. Adams MJ, Lefkowitz EJ, King AM, Harrach B, Harrison RL, Knowles
NJ, et al. Ratification vote on taxonomic proposals to the In-
ternational Committee on Taxonomy of Viruses (2016). Arch Vi-
rol. 2016;161(10):2921–49. doi: 10.1007/s00705-016-2977-6. [PubMed:
27424026]. [PubMed Central: PMC7086986].
4. Walker PJ, Siddell SG, Lefkowitz EJ, Mushegian AR, Dempsey DM,
Dutilh BE, et al. Changes to virus taxonomy and the International
Code of Virus Classification and Nomenclature ratified by the In-
ternational Committee on Taxonomy of Viruses (2019). Arch Vi-
rol. 2019;164(9):2417–29. doi: 10.1007/s00705-019-04306-w. [PubMed:
31187277].
5. Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR.
Homology-based identification of a mutation in the coronavirus
RNA-dependent RNA polymerase that confers resistance to multi-
ple mutagens. J Virol. 2016;90(16):7415–28. doi: 10.1128/JVI.00080-16.
[PubMed: 27279608]. [PubMed Central: PMC4984655].
6. Fehr AR, Perlman S. Coronaviruses: An overview of their replication
and pathogenesis. Methods Mol Biol. 2015;1282:1–23. doi: 10.1007/978-1-
4939-2438-7_1. [PubMed: 25720466]. [PubMed Central: PMC4369385].
7. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources
of endemic human coronaviruses. Adv Virus Res. 2018;100:163–88.
doi: 10.1016/bs.aivir.2018.01.001. [PubMed: 29551135]. [PubMed Cen-
tral: PMC7112090].
8. Riou J, Althaus CL. Pattern of early human-to-human transmis-
sion of Wuhan 2019 novel coronavirus (2019-nCoV), December
2019 to January 2020. Euro Surveill. 2020;25(4). doi: 10.2807/1560-
7917.ES.2020.25.4.2000058. [PubMed: 32019669]. [PubMed Central:
PMC7001239].
9. Principi N, Bosis S, Esposito S. Effects of coronavirus infections in chil-
dren. Emerg Infect Dis. 2010;16(2):183–8. doi: 10.3201/eid1602.090469.
[PubMed: 20113545]. [PubMed Central: PMC2957994].
10. Forgie S, Marrie TJ. Healthcare-associated atypical pneumonia. Semin
Respir Crit Care Med. 2009;30(1):67–85. doi: 10.1055/s-0028-1119811.
[PubMed: 19199189].
11. Zhang Z, Li X, Zhang W, Shi ZL, Zheng Z, Wang T. Clinical features
and treatment of 2019-nCov pneumonia patients in Wuhan: Report
of a couple cases. Virol Sin. 2020. doi: 10.1007/s12250-020-00203-8.
[PubMed: 32034637].
12. Isaacs D, Flowers D, Clarke JR, Valman HB, MacNaughton MR. Epi-
demiology of coronavirus respiratory infections. Arch Dis Child.
1983;58(7):500–3. doi: 10.1136/adc.58.7.500. [PubMed: 6307189].
[PubMed Central: PMC1628163].
13. Arbour N, Ekande S, Cote G, Lachance C, Chagnon F, Tardieu M, et al.
Persistent infection of human oligodendrocytic and neuroglial cell
lines by human coronavirus 229E. J Virol. 1999;73(4):3326–37. [PubMed:
10074187]. [PubMed Central: PMC104097].
14. Jacomy H, Talbot PJ. Vacuolating encephalitis in mice infected
by human coronavirus OC43. Virology. 2003;315(1):20–33. doi:
10.1016/s0042-6822(03)00323-4. [PubMed: 14592756]. [PubMed
Central: PMC7126296].
Iran J Pediatr. In Press(In Press):e102569. 3
Uncorrected Proof
Ashrafi MR et al.
15. Morfopoulou S, Brown JR, Davies EG, Anderson G, Virasami A, Qasim
W, et al. Human coronavirus OC43 associated with fatal encephalitis.
N Engl J Med. 2016;375(5):497–8. doi: 10.1056/NEJMc1509458. [PubMed:
27518687].
16. Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term hu-
man coronavirus-myelin cross-reactive T-cell clones derived from
multiple sclerosis patients. Clin Immunol. 2007;123(3):258–67. doi:
10.1016/j.clim.2007.02.002. [PubMed: 17448727]. [PubMed Central:
PMC7106099].
17. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by hu-
man respiratory coronaviruses. J Virol. 2000;74(19):8913–21. doi:
10.1128/jvi.74.19.8913-8921.2000. [PubMed: 10982334]. [PubMed Cen-
tral: PMC102086].
18. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, et
al. Severe neurologic syndrome associated with Middle East respira-
tory syndrome corona virus (MERS-CoV). Infection. 2015;43(4):495–501.
doi: 10.1007/s15010-015-0720-y. [PubMed: 25600929]. [PubMed Cen-
tral: PMC4521086].
19. Dominguez SR, Robinson CC, Holmes KV. Detection of four human
coronaviruses in respiratory infections in children: A one-year study
in Colorado. J Med Virol. 2009;81(9):1597–604. doi: 10.1002/jmv.21541.
[PubMed: 19626607]. [PubMed Central: PMC2879166].
20. Brison E, Jacomy H, Desforges M, Talbot PJ. Glutamate excitotoxicity
is involved in the induction of paralysis in mice after infection by a
human coronavirus with a single point mutation in its spike protein. J
Virol. 2011;85(23):12464–73. doi: 10.1128/JVI.05576-11. [PubMed: 21957311].
[PubMed Central: PMC3209392].
21. Turgay C, Emine T, Ozlem K, Muhammet SP, Haydar AT. A rare cause
of acute flaccid paralysis: Human coronaviruses. J Pediatr Neurosci.
2015;10(3):280–1. doi: 10.4103/1817-1745.165716. [PubMed: 26557177].
[PubMed Central: PMC4611905].
22. Kim JE, Heo JH, Kim HO, Song SH, Park SS, Park TH, et al. Neurologi-
cal complications during treatment of Middle East respiratory syn-
drome. J Clin Neurol. 2017;13(3):227–33. doi: 10.3988/jcn.2017.13.3.227.
[PubMed: 28748673]. [PubMed Central: PMC5532318].
4 Iran J Pediatr. In Press(In Press):e102569.
